Navigation Links
Pharmathene Reports Third Quarter 2008 Financial and Operational Results
Date:11/13/2008

ANNAPOLIS, Md., Nov. 13 /PRNewswire-FirstCall/ -- PharmAthene, Inc. (NYSE Alternext US: PIP), a biodefense company developing medical countermeasures against biological and chemical threats, today reported financial and operational results for the third quarter and nine months ended September 30, 2008.

For the third quarter of 2008, PharmAthene recognized revenues of $10.7 million compared to $3.4 million in the same period of 2007. For the nine months ended September 30, 2008 and 2007, the Company reported revenues of $27.4 million and $8.7 million, respectively. These revenues consisted primarily of contract funding from the U.S. government for the development of the Company's medical countermeasures, Protexia(R), SparVax(TM) and RypVax(TM). As a result of the Avecia vaccines acquisition in the second quarter of 2008, and particularly the acquired U.S. government contracts supporting the development of the rPA anthrax vaccines and RypVax(TM) plague vaccine product candidates, revenues for the three and nine month periods ended September 30, 2008 were further boosted by $5.5 million and $8.9 million, respectively.

Research and development expenses were $9.4 million and $3.6 million for the quarter ended September 30, 2008 and 2007, respectively. For the nine months ended September 30, 2008 and 2007, research and development expenses were $26.5 million and $10.7 million, respectively. Expenses for the third quarter and nine months of 2008 resulted from research and development activities related to programs for Valortim(R) and Protexia(R) as well as expenses related to the Company's SparVax(TM) and RypVax(TM) programs, which were acquired in the second quarter of 2008. The increase in research and development expenses is primarily due to process development expenses, manufacturing activities and clinical development expenses related to the Company's programs.

General and administrative expenses for the Company were $4.8 million and $3.2 m
'/>"/>

SOURCE PharmAthene, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related biology technology :

1. PharmAthene to Host Third Quarter 2008 Conference Call and Webcast on Thursday, November 13, 2008
2. PharmAthene to Present on Wednesday, November 12th at the 10th Annual Rodman & Renshaw Healthcare Conference
3. Medarex And PharmAthene Announce New Therapeutic Data for Anthrax Anti-Toxin, Valortim(R)
4. PharmAthene and Panacea Biotec Ltd. Establish Strategic Alliance in Biodefense and Emerging Infectious Diseases
5. PharmAthene Awarded NIAID Contract For Up to $83.9 Million For Third Generation rPA Anthrax Vaccine Program
6. PharmAthene to Present Data for Protexia(R) and Valortim(R) at HHS PHEMCE Stakeholders Workshop 2008
7. PharmAthene to Present at the UBS Global Life Sciences Conference on Thursday September 25, 2008
8. PharmAthene Response to DHHS Request for Proposals for Recombinant Protective Antigen Anthrax Vaccine Deemed Technically Acceptable and Within Competitive Range for Procurement Consideration
9. PharmAthene Reports Second Quarter 2008 Financial and Operational Results
10. Lord Lewis Moonie to Serve as Special UK Government Advisor to PharmAthene
11. PharmAthene Appoints Jordan P. Karp, J.D. Senior Vice President and General Counsel
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/3/2015)... 2015  MiMedx Group, Inc. (NASDAQ: MDXG ), ... and patent-protected processes to develop and market advanced products ... Sports Medicine, Ophthalmic and Dental sectors of healthcare, announced ... Annual Canaccord|Genuity Growth Conference in Boston, ... CEO, William C. Taylor , President and COO, ...
(Date:8/3/2015)... -- Merck KGaA, Darmstadt, Germany ,  a ... the healthcare, life science and performance materials sectors, announced ... and launch of promising new fullerene derivatives for the ... Germany , is pursuing many projects ... Novel derivatives: highly stable, easy to process and cost ...
(Date:8/3/2015)... 2015  Aethlon Medical, Inc. (Nasdaq: AEMD ), ... life-threatening diseases, today announced that it will host its ... on Thursday, August 13, 2015 at 4:30 p.m. Eastern ... the release of fiscal 2016 first quarter results.  A ... two hours after the call at the Investor Relations ...
(Date:8/3/2015)... Aug. 3, 2015   Intrexon Corporation (NYSE: ... half and second quarter 2015 financial results after the ... The Company will host a conference call at 5:30 ... general business update. The conference call may ... (International), and asking to join the "Intrexon Corporation Call."  ...
Breaking Biology Technology:MiMedx To Present At 35th Annual Canaccord|Genuity Growth Conference 2Merck KGaA, Darmstadt, Germany, and Nano-C Present Enhanced Materials for Organic Photovoltaics 2Merck KGaA, Darmstadt, Germany, and Nano-C Present Enhanced Materials for Organic Photovoltaics 3Merck KGaA, Darmstadt, Germany, and Nano-C Present Enhanced Materials for Organic Photovoltaics 4Aethlon Medical To Host First Quarter Fiscal 2016 Investor Call on August 13, 2015 2Intrexon to Announce First Half and Second Quarter 2015 Financial Results and Host Conference Call on August 10th 2
... 2011 Reportlinker.com announces that a ... in its catalogue: What,s ... and Other Biologics) 2011-2015 ... future of the pharmaceutical market will ...
... aid the fight of the deadly outbreak of E. ... at the University Medical Centre Hamburg-Eppendorf have released an ... data previously released and submitted to NCBI in the ... assembled using the latest ion semiconductor sequencing technology, there ...
... Asmacure Ltee, a clinical-stage biopharmaceutical company focused ... treatment of asthma and other inflammatory diseases, announced today ... officer.  With a solid foundation established at Asmacure, Mr. ... lead compound, a potential new treatment for asthma with ...
Cached Biology Technology:Reportlinker Adds What's Next in Biologics? (mAbs, rDNA, Interferons, and Other Biologics) 2011-2015 2Reportlinker Adds What's Next in Biologics? (mAbs, rDNA, Interferons, and Other Biologics) 2011-2015 3Reportlinker Adds What's Next in Biologics? (mAbs, rDNA, Interferons, and Other Biologics) 2011-2015 4Reportlinker Adds What's Next in Biologics? (mAbs, rDNA, Interferons, and Other Biologics) 2011-2015 5Reportlinker Adds What's Next in Biologics? (mAbs, rDNA, Interferons, and Other Biologics) 2011-2015 6Reportlinker Adds What's Next in Biologics? (mAbs, rDNA, Interferons, and Other Biologics) 2011-2015 7Further Analysis on Improved Genome Assembly Indicates the Outbreak E. coli has Complex Genetics With Resistance to at Least Eight Antibiotics 2Further Analysis on Improved Genome Assembly Indicates the Outbreak E. coli has Complex Genetics With Resistance to at Least Eight Antibiotics 3Asmacure Ltee Appoints Pharmaceutical and Biotechnology Industry Veteran Martin Driscoll as CEO 2Asmacure Ltee Appoints Pharmaceutical and Biotechnology Industry Veteran Martin Driscoll as CEO 3
(Date:7/27/2015)... , July 27, 2015   Zynx Health ... experience-based clinical improvement solutions, today announced that its ... now available on Android smartphones and tablets. With ... post-care organizations can use ZynxCarebook to securely exchange ... condition, streamline care transitions to other care settings, ...
(Date:7/21/2015)... Connecticut , July 21, 2015  NXT-ID, ... "Company"), a biometric authentication company focused on the ... Wocket® smart wallet, announces that it has filed ... System and Method. This invention ... not only authorizes an account, but also the ...
(Date:7/13/2015)... Jul. 13, 2015 NXT-ID, Inc. (NASDAQ: ... authentication company focused on the growing mobile commerce ... patent 62/188684 for BEHAVIORAL-DIRECTED AUTHENTIATION METHOD ... convenient and secure method to make payments.  With ... methods, introduced with its groundbreaking voice-direct payment patent ...
Breaking Biology News(10 mins):Zynx Health Adds Android Device Support to ZynxCarebook Solution 2Zynx Health Adds Android Device Support to ZynxCarebook Solution 3NXT-ID Patents Personalized Tokenized Payments for Next Generation Secure Payment Technology 2NXT-ID Patents Personalized Tokenized Payments for Next Generation Secure Payment Technology 3NXT-ID Patents Personalized Tokenized Payments for Next Generation Secure Payment Technology 4NXT-ID Patents Behavior-Directed Payments 2NXT-ID Patents Behavior-Directed Payments 3NXT-ID Patents Behavior-Directed Payments 4
... to hear relies on hair cells, sensory receptors that mechanically ... transduction channel. Although the transduction channel was characterized more than ... molecular components. A new study in The Journal ... definitive identification of this mystery channel. Recent studies ...
... a long and complex process. Candidate drugs are evaluated ... of animals, usually rats or mice. Each class of ... often in a labor-intensive process that leaves plenty of ... consensus that current procedures fail to effectively produce new ...
... Clinical Practice Guideline (CPG) for the diagnosis and treatment ... in women of reproductive age and a leading cause ... of Polycystic Ovary Syndrome: An Endocrine Society Clinical Practice ... the Journal of Clinical Endocrinology and Metabolism ...
Cached Biology News:Finding psychiatric drugs in the movements of mice 2Finding psychiatric drugs in the movements of mice 3Experts clarify conflicting criteria for diagnosing polycystic ovary syndrome 2
Rabbit polyclonal to Glutathione S Transferase alpha ( Abpromise for all tested applications). Antigen: Full length protein: Human Glutathione S Transferase alpha. Entrez GeneID: 2938 Swi...
Affinity Purified Rabbit Anti-mouse sRANKL Biotinylated Polyclonal Antibody...
Mouse anti-IkBa/MAD-3 Class: Antibody Product Group: Signalling molecules and phospho-specific Antibody...
Mouse monoclonal [002-49] to C1s ( Abpromise for all tested applications). entrezGeneID: 716 SwissProtID: P09871...
Biology Products: